Tocqueville Asset Management L.P. Sells 5,559 Shares of Edwards Lifesciences Corporation (EW)

Tocqueville Asset Management L.P. decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 11.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,730 shares of the medical research company’s stock after selling 5,559 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Edwards Lifesciences Corporation were worth $4,889,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sabal Trust CO boosted its holdings in shares of Edwards Lifesciences Corporation by 0.5% during the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares during the period. Alps Advisors Inc. grew its position in shares of Edwards Lifesciences Corporation by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after buying an additional 14 shares during the period. Alexandria Capital LLC grew its position in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the period. Veritable L.P. grew its position in shares of Edwards Lifesciences Corporation by 1.2% during the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after buying an additional 71 shares during the period. Finally, First Bank & Trust grew its position in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock worth $525,000 after buying an additional 76 shares during the period. Institutional investors own 82.17% of the company’s stock.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total transaction of $594,395.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total value of $104,150.00. Following the transaction, the director now owns 2,622 shares in the company, valued at $273,081.30. The disclosure for this sale can be found here. Insiders have sold a total of 139,580 shares of company stock valued at $15,143,994 in the last three months. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation (NYSE:EW) traded down $0.09 during trading on Wednesday, hitting $105.15. The stock had a trading volume of 994,900 shares, compared to its average volume of 1,644,831. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. The firm has a market capitalization of $22,250.00, a P/E ratio of 29.15, a P/E/G ratio of 1.89 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 EPS. equities research analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.

Several brokerages have recently commented on EW. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price target (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Barclays PLC reissued an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Saturday, September 30th. Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Cowen and Company reaffirmed an “outperform” rating and issued a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Deutsche Bank AG cut their price target on shares of Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a research note on Thursday, October 26th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $125.17.

ILLEGAL ACTIVITY NOTICE: “Tocqueville Asset Management L.P. Sells 5,559 Shares of Edwards Lifesciences Corporation (EW)” was published by Week Herald and is owned by of Week Herald. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://weekherald.com/2017/11/15/edwards-lifesciences-corporation-ew-shares-sold-by-tocqueville-asset-management-l-p.html.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply